Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mehrdad Mobasher, MD, MPH
Corvus Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Brisbane and Women'S Hospital
Brisbane, Queensland, Australia
- Monash Health
Clayton, Victoria, Australia
- Cross Cancer Institute
Edmonton, Alberta, Canada
- British Columbia Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- University of Arizona Cancer Center
Tucson, Arizona, United States
- University of California - San Francisco
San Francisco, California, United States
- Stanford Cancer Institute
Stanford, California, United States
- Yale University
New Haven, Connecticut, United States
- University of Miami Hospital and Clinics
Miami, Florida, United States
- Rush University Medical Center
Chicago, Illinois, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- University of Pittsburgh Medical Center Cancer Center
Pittsburgh, Pennsylvania, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2016
- Primary completion
- 30 Jun 2021
- Completion
- 31 Jul 2021
- Last update posted
- 30 Aug 2021
- Registered enrollment
- 502
- Registry id
- NCT02655822
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.